Related content

Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II

By Papp Kim   Camisa Charles   Stone Stephen   Caro Ivor   Wang Xiaolin   Compton Peter   Walicke Patricia   Gottlieb Alice  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 6, 2005-12 ,pp. : 313-323

Springer Publishing Company

Access to resources Recommend Favorite

The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit–risk assessment of finasteride and dutasteride

By Gupta Aditya K   Charrette Andrew  

Journal of Dermatological Treatment, Vol. 25, Iss. 2, 2014-04 ,pp. : 156-161

Informa Healthcare

Access to resources Recommend Favorite

Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice

By Berends Maartje A. M.   Driessen Rieke J. B.   Langewouters Annechien M. G.   Boezeman Jan B.   van de Kerkhof Peter C. M.   de Jong Elke M. G. J.  

Journal of Dermatological Treatment, Vol. 18, Iss. 2, 2007-01 ,pp. : 76-83

Informa Healthcare

Access to resources Recommend Favorite

The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab

By Pincelli Carlo  

Archives of Dermatological Research, Vol. 298, Iss. 7, 2006-12 ,pp. : 329-338

Springer Publishing Company

Access to resources Recommend Favorite

Clinical Efficacy of Efalizumab in Patients With Chronic Plaque Psoriasis: Results From Three Randomized Placebo-Controlled Phase III Trials: Part I

By Pariser David   Gordon Kenneth   Papp Kim   Leonardi Craig   Kwon Paul   Compton Peter   Rundle Amy   Walicke Patricia   Lebwohl Mark  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 6, 2005-12 ,pp. : 303-312

Springer Publishing Company

Access to resources Recommend Favorite